Response to Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”-Reference-Cited by-同舟云学术

Response to Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”

Published:2023-01-12 Issue:2 Volume:43 Page:149-150
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Durga Devarapalli Ranjani,Mounika Nadella,Mudimala Pravallika,Adela Ramu^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-022-01244-5.pdf

Reference10 articles.

1. Dutta D, Mohindra R, Misra A. Comment on: “Efficacy and safety of saroglitazar in patients with cardiometabolic diseases: a systematic review and meta-analysis of randomized controlled trials”. Clin Drug Investig. 2023. https://doi.org/10.1007/s40261-022-01245-4.

2. Robert RH, Lincoff AM, Sunder M, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374:126–35.

3. Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;20:2061–71.

4. Sosale A, Saboo B, Sosale B. Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence. Diabetes Metab Syndr Obes Targets Ther. 2015;8:189.

5. Durga DR, Mounika N, Mudimala P, Adela R. Efficacy and safety of saroglitazar in patients with cardiometabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2022;42(12):1049–64.